BARD1 expression predicts outcome in colon cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The BARD1 gene interacts with BRCA1 and possesses tumor-suppressive functions.
• Aberrant BARD1 splice variants have been observed in various cancers, with some potentially being cancer-specific.
• This study is the first to investigate BARD1 expression patterns and their correlation with clinical outcomes in colon cancer.

Purpose of the Study:

• To assess BARD1 expression patterns in colon cancer.
• To identify and characterize BARD1 splice variants in colon cancer.
• To determine the correlation between BARD1 expression and clinical outcome in colon cancer patients.

Main Methods:

• Analysis of colon cancer samples for BARD1 splice variants.
• Characterization of novel BARD1 splice variants.
• Quantification of mRNA expression levels of BARD1 isoforms in cancerous and normal colon tissues.
• Correlation analysis of full-length BARD1 protein expression with clinical outcome.

Main Results:

• Nineteen distinct BARD1 splice variants were identified in colon cancer, alongside full-length BARD1 mRNA.
• These splice variants were also found in adjacent normal colon tissue, challenging previous assumptions.
• While splice variants are prevalent, specific variants exhibit cancer-specific regulation patterns.
• Expression of full-length BARD1 protein is a significant predictor of outcome in colon cancer, with loss of expression correlating with poor prognosis (P = 0.0002).

Conclusions:

• BARD1 regulation represents a critical pathway in colon cancer development and progression.
• Full-length BARD1 protein shows potential as a valuable biomarker for improving risk stratification in colon cancer patients.